Market By Therapeutic Application, Product, Analysis Purpose, End-user, Analysis Platform, Biomarker Type, Clinical Application And Geography | Forecast 2019-2027
The detailed analysis of the global liquid biopsy market shows that in terms of revenue, the industry is estimated to grow at a CAGR of 21.54% during the forecasting years 2019-2027. The market was assessed to be worth $886.44 million in the year 2018 and is predicted to generate a revenue of approximately $5114.47 million by the year 2027.
Report scope can be customized per your requirements. Request For Customization
Liquid biopsy tests are performed across healthcare and research settings to understand the molecular aspects of cancer. These tests are carried out by hospitals, physicians and pathological & research laboratories and provide the researchers, physicians & surgeons with information about the cancer profile of the patient. This helps in determining appropriate therapy to improve the survival rate of cancer patients.
A liquid biopsy is performed on a blood sample so that cancer cells can be detected in the circulating blood. A liquid biopsy is one of the most prominent tests that is used to detect cancer at an early stage; it helps in deciding the necessary treatment and also to check for effectiveness of the treatment as well as the repeated occurrence of a tumor, during and after the cancer treatment. Multiple blood samples are taken over some time to understand the molecular changes that take place in a tumor. The study aims to get an overview of the liquid biopsy market in terms of various factors such as the recent trends, technological advancements and the regulatory aspects of the market. Due to the growing demand for non-invasive diagnostic procedures, the global liquid biopsy market is expected to hit an impressive double-digit growth rate over the forecast period.
Within this report, the market definition and the key insights regarding the liquid biopsy industry have been discussed. Also, Porter's five force analysis, the regulatory framework, key market trends, market attractiveness index and the key initiatives have been studied in detail.
Market drivers like the increasing cases of cancer in the aging population, increase in different initiatives taken by the government, demand for diagnostic centers, increase in the tissue/tumor-agnostic drugs usage and the growing adoption of precision medicine are driving this market. However, the industry is facing market restraints like the high cost of test and a lack of a consensus on standard operating procedures, which are obstructing the industry growth. Key opportunities like advancement in technology and the increasing number of cancer patients can be leveraged by the industry to reach the projected growth. However, challenges such as the lack of reimbursements and fewer skilled professionals are being faced by this market.
To get detailed insights on segments, Download Sample Report
Geographies covered in the global liquid biopsy market are:
• North America: the United States and Canada
• Europe: the United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe
• Asia-Pacific: Japan, China, India, ASEAN countries, South Korea, Australia & New Zealand and Rest of Asia-Pacific
• Latin America: Mexico, Brazil and Rest of Latin America
• The Middle East and Africa: Turkey, the United Arab Emirates, South Africa, Saudi Arabia and Rest of the Middle East & Africa
The liquid biopsy market has been segmented as follows:
• By Clinical Application
O Treatment Monitoring
O Prognosis & Reoccurrence Monitoring
O Treatment Selection
O Diagnosis & Screening
• By Product
O Circulating Tumor DNA (cTDNA)
O Cell-Free DNA (cfDNA)
O Circulating Tumor Cells (CTCs)
O Extracellular vesicles and Others
• By Analysis Purpose
O Monitoring
O Therapy guidance
O Diagnosis
O Early detection/screening
• By End-User
O Hospitals
O Physicians’ office laboratories
O Clinical diagnostic laboratories
• By Analysis Platform
O NGS
O Microarray
O PCR
O Proteomics
O Other analysis platforms
• By Biomarker Type
O Nucleic acids
O Proteins
O Extracellular vesicles
O Cells
• By Therapeutic Application
O Lung Cancer
O Breast Cancer
O Prostate Cancer
O Colorectal Cancer
O Melanoma Cancer
O Other types of cancer
O Non-Oncology Applications
The top companies that have been studied in the global liquid biopsy market are Agilent Technologies, Inc., Boston Scientific Corporation, Argon Medical Devices, Inc., B. Braun Melsungen AG, Cintec Medical Ltd., Roche Diagnostics Corporation, Ad-Tech Medical Instrument Corp., I.M.S. Internazionale Medico Scientifica Srl, QIAGEN N.V., Becton, Dickinson, Planmeca Oy, Bio-Rad Laboratories, Inc., Cardinal Health, Inc., Cook Medical, Inc., Fischer Medical Technologies LLC, C. R. Bard, Inc. (acquired by Becton, Dickinson and Company)
The strategic analysis for each of these companies has been covered in detail. The company market share helps to dive into the information about the key market players in this industry and how much hold they have on the market.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Test Types, Technolo ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT1.
GLOBAL LIQUID BIOPSY MARKET - SUMMARY
2.
INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1.
THREAT OF NEW ENTRANTS
2.3.2.
THREAT OF SUBSTITUTES
2.3.3.
BARGAINING POWER OF BUYERS
2.3.4.
BARGAINING POWER OF SUPPLIERS
2.3.5.
THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1.
CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2.
INCREASE IN DIFFERENT INITIATIVES TAKEN BY THE GOVERNMENT
2.8.3.
DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.4.
TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.5.
RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1.
HIGH COST OF TEST
2.9.2.
LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10.
MARKET OPPORTUNITIES
2.10.1.
ADVANCEMENT IN TECHNOLOGY
2.10.2.
RISING NUMBER OF CANCER PATIENTS
2.11.
MARKET CHALLENGES
2.11.1.
LACK OF REIMBURSEMENT
2.11.2.
SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBER
3.
LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4.
LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5.
LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6.
LIQUID BIOPSY MARKET OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7.
LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8.
LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPE
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9.
LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1.
NORTH AMERICA
10.1.1.
MARKET BY THERAPEUTIC APPLICATION
10.1.2.
MARKET BY CLINICAL APPLICATION
10.1.3.
MARKET BY BIOMARKER TYPE
10.1.4.
MARKET BY ANALYSIS PLATFORM
10.1.5.
MARKET BY ANALYSIS PURPOSE
10.1.6.
MARKET BY PRODUCT
10.1.7.
MARKET BY END-USER
10.1.8.
COUNTRY ANALYSIS
10.1.8.1.
THE UNITED STATES
10.1.8.2.
CANADA
10.2.
EUROPE
10.2.1.
MARKET BY THERAPEUTIC APPLICATION
10.2.2.
MARKET BY CLINICAL APPLICATION
10.2.3.
MARKET BY BIOMARKER TYPE
10.2.4.
MARKET BY ANALYSIS PLATFORM
10.2.5.
MARKET BY ANALYSIS PURPOSE
10.2.6.
MARKET BY PRODUCT
10.2.7.
MARKET BY END-USER
10.2.8.
COUNTRY ANALYSIS
10.2.8.1.
THE UNITED KINGDOM
10.2.8.2.
FRANCE
10.2.8.3.
GERMANY
10.2.8.4.
ITALY
10.2.8.5.
SPAIN
10.2.8.6.
RUSSIA
10.2.8.7.
REST OF EUROPE
10.3.
ASIA-PACIFIC
10.3.1.
MARKET BY THERAPEUTIC APPLICATION
10.3.2.
MARKET BY CLINICAL APPLICATION
10.3.3.
MARKET BY BIOMARKER TYPE
10.3.4.
MARKET BY ANALYSIS PLATFORM
10.3.5.
MARKET BY ANALYSIS PURPOSE
10.3.6.
MARKET BY PRODUCT
10.3.7.
MARKET BY END-USER
10.3.8.
COUNTRY ANALYSIS
10.3.8.1.
JAPAN
10.3.8.2.
CHINA
10.3.8.3.
INDIA
10.3.8.4.
SOUTH KOREA
10.3.8.5.
ASEAN COUNTRIES
10.3.8.6.
AUSTRALIA & NEW ZEALAND
10.3.8.7.
REST OF ASIA-PACIFIC
10.4.
LATIN AMERICA
10.4.1.
MARKET BY THERAPEUTIC APPLICATION
10.4.2.
MARKET BY CLINICAL APPLICATION
10.4.3.
MARKET BY BIOMARKER TYPE
10.4.4.
MARKET BY ANALYSIS PLATFORM
10.4.5.
MARKET BY ANALYSIS PURPOSE
10.4.6.
MARKET BY PRODUCT
10.4.7.
MARKET BY END-USER
10.4.8.
COUNTRY ANALYSIS
10.4.8.1.
BRAZIL
10.4.8.2.
MEXICO
10.4.8.3.
REST OF LATIN AMERICA
10.5.
MIDDLE EAST AND AFRICA
10.5.1.
MARKET BY THERAPEUTIC APPLICATION
10.5.2.
MARKET BY CLINICAL APPLICATION
10.5.3.
MARKET BY BIOMARKER TYPE
10.5.4.
MARKET BY ANALYSIS PLATFORM
10.5.5.
MARKET BY ANALYSIS PURPOSE
10.5.6.
MARKET BY PRODUCT
10.5.7.
MARKET BY END-USER
10.5.8.
COUNTRY ANALYSIS
10.5.8.1.
SAUDI ARABIA
10.5.8.2.
TURKEY
10.5.8.3.
THE UNITED ARAB EMIRATES
10.5.8.4.
SOUTH AFRICA
10.5.8.5.
REST OF MIDDLE EAST & AFRICA
11. COMPETITIVE LANDSCAPE
11.1.
AGILENT TECHNOLOGIES, INC.
11.2.
BOSTON SCIENTIFIC CORPORATION
11.3.
ARGON MEDICAL DEVICES, INC.
11.4.
B. BRAUN MELSUNGEN AG
11.5.
CINTEC MEDICAL LTD.
11.6.
ROCHE DIAGNOSTICS CORPORATION
11.7.
AD-TECH MEDICAL INSTRUMENT CORP.
11.8.
I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9.
QIAGEN N.V.
11.10.
BECTON, DICKINSON
11.11.
PLANMECA OY
11.12.
BIO-RAD LABORATORIES, INC.
11.13.
CARDINAL HEALTH, INC.
11.14.
COOK MEDICAL, INC.
11.15.
FISCHER MEDICAL TECHNOLOGIES LLC
11.16.
C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1.
RESEARCH SCOPE & DELIVERABLES
12.1.1.
OBJECTIVES OF STUDY
12.1.2.
SCOPE OF STUDY
12.2.
SOURCES OF DATA
12.2.1.
PRIMARY DATA SOURCES
12.2.2.
SECONDARY DATA SOURCES
12.3.
RESEARCH METHODOLOGY
12.3.1.
EVALUATION OF PROPOSED MARKET
12.3.2.
IDENTIFICATION OF DATA SOURCES
12.3.3.
ASSESSMENT OF MARKET DETERMINANTS
12.3.4.
DATA COLLECTION
12.3.5.
DATA VALIDATION & ANALYSIS
TABLE 1 GLOBAL
LIQUID BIOPSY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 2 LIQUID
BIOPSY BIOMARKER CLASSES
TABLE 3 GOVERNMENT
INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
TABLE 4 GLOBAL
LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 5 GLOBAL
LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 6 GLOBAL
LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 7 GLOBAL
LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 8 GLOBAL
LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 9 ADVANTAGES
OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 10 DROPLET
DIGITAL PCR INDUSTRIES
TABLE 11 GLOBAL
LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 12 CELL
DIFFERENTIATORS
TABLE 13 GLOBAL
LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 14 GLOBAL
LIQUID BIOPSY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 15 NORTH
AMERICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 16 NORTH
AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 17 NORTH
AMERICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 18 NORTH
AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 19 NORTH
AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 20 NORTH
AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 21 NORTH
AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 22 NORTH
AMERICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 23 EUROPE
LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 24 EUROPE
LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 25 EUROPE
LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 26 EUROPE
LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 27 EUROPE
LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 28 EUROPE
LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 29 EUROPE
LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 30 EUROPE
LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 31 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 32 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 33 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 34 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 35 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 36 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 37 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 38 ASIA-PACIFIC
LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 39 LATIN
AMERICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 40 LATIN
AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 41 LATIN
AMERICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 42 LATIN
AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 43 LATIN
AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 44 LATIN
AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 45 LATIN
AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 46 LATIN
AMERICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 47 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 48 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($
MILLION)
TABLE 49 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($
MILLION)
TABLE 50 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 51 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 52 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 53 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 54 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
FIGURE 1 GLOBAL
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 2 RURAL
POPULATIONS IN DEVELOPING COUNTRIES 2017 (%)
FIGURE 3 GLOBAL
LIQUID BIOPSY MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 4 GLOBAL
LIQUID BIOPSY MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 5 TYPES
OF BREAST CANCER
FIGURE 6 GLOBAL
LIQUID BIOPSY MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 7 GLOBAL
LIQUID BIOPSY MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL
LIQUID BIOPSY MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL
LIQUID BIOPSY MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL
LIQUID BIOPSY MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL
LIQUID BIOPSY MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL
LIQUID BIOPSY MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL
LIQUID BIOPSY MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL
LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL
LIQUID BIOPSY MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL
LIQUID BIOPSY MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL
LIQUID BIOPSY MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL
LIQUID BIOPSY MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL
LIQUID BIOPSY MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL
LIQUID BIOPSY MARKET BY PHYSICIANS’ OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 GLOBAL
LIQUID BIOPSY MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 22 GLOBAL
LIQUID BIOPSY MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL
LIQUID BIOPSY MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 24 GLOBAL
LIQUID BIOPSY MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 25 GLOBAL
LIQUID BIOPSY MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL
LIQUID BIOPSY MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL
LIQUID BIOPSY MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 28 GLOBAL
LIQUID BIOPSY MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 29 GLOBAL
LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 30 GLOBAL
LIQUID BIOPSY MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 31 GLOBAL
LIQUID BIOPSY MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 32 GLOBAL
LIQUID BIOPSY MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($
MILLION)
FIGURE 33 GLOBAL
LIQUID BIOPSY MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 34 GLOBAL
LIQUID BIOPSY MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 35 NORTH
AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 36 THE
UNITED STATES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 37 NEW
CANCER CASES & CANCER DEATHS IN THE US 2016-2020 (PER 100,000 PEOPLE)
FIGURE 38 CANADA
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 39 EUROPE
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 40 THE
UNITED KINGDOM LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 41 FRANCE
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 42 GERMANY
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 43 ITALY
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 44 SPAIN
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 45 RUSSIA
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 46 REST
OF EUROPE LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 47 ASIA-PACIFIC
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 48 JAPAN
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 49 CHINA
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 50 INDIA
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 51 SOUTH
KOREA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 52 AUSTRALIA
& NEW ZEALAND LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 53 ASEAN
COUNTRIES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 54 REST
OF ASIA-PACIFIC LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 55 LATIN
AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 56 BRAZIL
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 57 MEXICO
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 58 REST
OF LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 59 MIDDLE
EAST AND AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 60 SAUDI
ARABIA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 61 TURKEY
LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 62 UNITED
ARAB EMIRATES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 63 SOUTH
AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 64 REST
OF MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)